The new coronavirus SARS-CoV-2 was identified to be responsible for the COVID-19 pandemic. There are striking differences in the response to infection, some people develop no or mild symptoms, while other outcomes are severe of even fatal. For those COVID-19 patients who require hospitalization, prognostic markers could help clinicians to identify patients with a poor outcome early. The serum levels of the immune activation marker neopterin have already been shown to be of prognostic value in patients with SARS-CoV-1 and a similar pattern can be observed for SARS-CoV-2. This comment discusses the biochemical circuits that support the clinical value of neopterin measurements in COVID-19 patients.

中文翻译：

---

新蝶呤测定对COVID-19感染患者的实验室诊断价值

新的冠状病毒SARS-CoV-2被确定与COVID-19大流行有关。对感染的反应存在显着差异，有些人没有症状或症状轻微，而另一些后果则严重甚至致命。对于那些需要住院的COVID-19患者，预后标志物可以帮助临床医生及早发现结局较差的患者。免疫激活标记新蝶呤的血清水平已经显示出对SARS-CoV-1患者具有预后价值，对于SARS-CoV-2可以观察到类似的模式。该评论讨论了支持COVID-19患者中新蝶呤测量的临床价值的生化回路。